Harnessing the Host Response for Real Time Clinical Decision Making in Infectious Diseases


In his lecture, Dr. Woods will describe the emerging pandemic of antimicrobial resistance and how his 20-year obsession with developing improved diagnostics for infectious diseases addresses the problem. In particular, he will discuss the derivation of host mRNA signatures, their translation to new diagnostic platforms, and the clinical trials designed to assess their performance.

Originally presented on December 20, 2018 in Salt Lake City, Utah.

Lecture Presenter

Christopher W. Woods, MD, MPH, FIDSA

Christopher W. Woods, MD, MPH, FIDSA

Professor of Medicine, Pathology and Global Health
Duke University

Dr. Woods is a professor in the Departments of Medicine and Pathology at Duke University, adjunct associate professor in Epidemiology at the University of North Carolina-Chapel Hill School of Public Health, and adjunct associate professor in the Emerging Infections Program at the Duke-National University of Singapore Graduate Medical School. He is Co-Director of the Hubert-Yeargan Center for Global Health, and Associate Director for Applied Genomics in the Duke Center for Applied Genomics & Precision Medicine (CAGPM). Dr. Woods is the Global Health lead for the Duke Tropical Conservation Initiative. Clinically, he is Chief of Infectious Diseases, and hospital epidemiologist for the Durham VA Medical Center. Dr. Woods is board-certified in internal medicine, infectious diseases, and medical microbiology.

Dr. Woods has co-authored over 160 peer-reviewed articles. His research focuses on development of novel diagnostic approaches to infectious disease and potential for interspecies transmission of pathogens. His genomic approach to harnessing the host response for diagnosis of infectious diseases has been called a paradigm shift in the field. He is particularly interested in augmenting medical microbiology capacity in the developing world and epidemiology of emerging and re-emerging infectious diseases.


After this presentation, participants will be able to:

  • Describe the design, development, and commercialization strategy for novel host biomarkers related to infectious diseases
  • Review the diagnostic platform landscape that can accommodate mRNA multi-analyte biomarkers in an acute care setting

Sponsored by:

University of Utah School of Medicine, Department of Pathology, and ARUP Laboratories